Clinical Trials Logo
  1. Home
  2. Tuberculosis (TB)
  3. NCT01879163

Phase I Trial Evaluating Safety and Immunogenicity of MVA85A-IMX313 Compared to MVA85A in BCG Vaccinated Adults

Tuberculosis (TB) Clinical Trial

Official title:
A Phase I Randomised Trial to Evaluate the Safety and Immunogenicity of MVA85A-IMX313 Compared to MVA85A in Bacille Calmette-Guérin (BCG) Vaccinated Adults

Clinical Trial Summary

This is a Phase I trial to evaluate the safety and immunogenicity of MVA85A-IMX313 vaccination compared to MVA85A vaccination, in BCG vaccinated adults.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01879163
Study type Interventional
Source University of Oxford
Contact
Status Completed
Phase Phase 1
Start date July 2013
Completion date December 2014
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06272812 - A Study to Evaluate the Efficacy, Safety and Immunogenicity of MTBVAC in IGRA Positive Adolescents and Adults Living in a TB Endemic Region. Phase 2
Active, not recruiting NCT01875952 - Diagnosis and Treatment of Co-infection With Human Immunodeficiency Virus /Latent Tuberculosis Infection (HIV/TBL) Phase 4
Completed NCT03929705 - Assessing the Ability of the T-SPOT®.TB Test
Recruiting NCT03808636 - Innovative Reagents for Improving Rapid Diagnosis of Mycobacterial Infections
Completed NCT00146744 - Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mtb72F/AS02A in Healthy PPD-positive Adults Phase 2
Completed NCT00291889 - Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mtb72F/AS02 in Healthy PPD-negative Adults. Phase 1
Recruiting NCT04333485 - Tuberculosis (TB) Aftermath N/A
Completed NCT00730795 - Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine Given to PPD-Negative Adults Phase 1
Completed NCT00600782 - Immunogenicity and Safety of a Candidate Tuberculosis (TB) Vaccine Given to Healthy Adults in a TB-endemic Region Phase 2
Withdrawn NCT04243031 - QuantiFERON Access Clinical Performance Study Protocol